Premium
Follow‐up after primary treatment of soft tissue sarcoma of extremities: Impact of frequency of follow‐up imaging on disease‐specific survival
Author(s) -
Chou YiSheng,
Liu ChunYu,
Chen WeiMing,
Chen TainHsiung,
Chen Paul ChihHsueh,
Wu HungTa Hondar,
Chiou HongJen,
Shiau ChengYing,
Wu YuChung,
Liu ChienLin,
Chao TaChung,
Tzeng ChengHwai,
Yen ChuehChuan
Publication year - 2012
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23060
Subject(s) - medicine , soft tissue sarcoma , soft tissue , surgical margin , sarcoma , confidence interval , overall survival , surgery , metastasis , retrospective cohort study , radiology , cancer , pathology
Background and Objectives We explored the impact of frequency of surveillance imaging on disease‐specific survival (DSS) in patients with extremity soft tissue sarcoma (STS). Methods Locoregional imaging (LRI) and chest imaging (CI) were used to detect local recurrence (LR) and distant metastasis (DM), respectively. Relapsing patients were retrospectively assigned to more frequent surveillance (MFS) or less frequent surveillance (LFS) groups, according to the median interval for each follow‐up modality. Outcome measures included overall DSS (O‐DSS), post‐LR DSS, and post‐DM DSS. Results We assigned 165 patients to three distinct risk groups according to tumor size (≤5 vs. >5 cm), depth (superficial‐ vs. deep‐seated), grade (I vs. II or III), and surgical margin (≥10 vs. <10 mm). Data for 80 patients who relapsed were analyzed. Among 50 high‐risk (with all four risk factors) relapsing patients, those in the MFS group for either LRI or CI had better O‐DSS (LRI, median 44.07 vs. 27.43 months, P = 0.008; CI, median 43.60 vs. 36.93 months, P = 0.036), post‐LR DSS (median 27.20 vs. 10.63 months, P = 0.028) and post‐DM DSS (median 13.20 vs. 6.24 months, P = 0.031). Conclusion More frequent follow‐up were associated with improved survival in high‐risk relapsing patients with extremity STS by providing greater opportunities for adequate reoperation. J. Surg. Oncol. 2012; 106:155–161. © 2012 Wiley Periodicals, Inc.